2013 May Still Be A Trough Year For Bristol As New Drugs Continue To Take Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol remains plagued by the loss of exclusivity for Plavix and setbacks in 2012, but the company hopes to paint a picture of growth as newly approved drugs begin to fill the revenue gap.
You may also be interested in...
Emerging Markets Earnings Roundup: Amgen, Bristol Myers Squibb (Part 1)
After tackling Brazil and Turkey, Amgen looks to ramp up in Japan and China, while BMS talks up its first-to-market opportunity for an all-oral hepatitis C regimen in Japan.
Dapagliflozin Faces Ominous Prospect Of New Trials
FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.